$Verve Therapeutics(VERV)$ Financial Times reports that Lilly in advanced s talks to acquire Verve for up to $1.3 billion, which would value VERV at " around double its current market cap ~$559M)--implying an acquisition price near $13 per share
$Verve Therapeutics(VERV)$ Financial Times reports that Lilly in advanced s talks to acquire Verve for up to $1.3 billion, which would value VERV at " around double its current market cap ~$559M)--implying an acquisition price near $13 per share
Comments